Key clinical point: Pracinostat plus azacitidine induced more complete remissions (CRs) than azacitidine alone in older patients with AML.
Major finding: The primary endpoint – CR, CR with incomplete recovery of blood counts, or morphologic leukemia-free state – occurred in 26 of 50 patients.
Study details: Phase 2 trial in 50 patients older than 65 years with newly diagnosed AML.
Disclosures: The study was supported by research funding from MEI Pharma. Dr. Garcia-Manero reported having no disclosures. Multiple coauthors reported financial relationships with MEI and others. One coauthor is an MEI employee.
Garcia-Manero G et al. Blood Adv. 2019 Feb 26;3(4):508-18.